- Home
- EMD vs DAWN Comparison
EMD vs DAWN Comparison
Compare EMD & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | DAWN |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.9M | 624.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EMD | DAWN |
|---|---|---|
| Price | $10.88 | $9.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $26.56 |
| AVG Volume (30 Days) | 248.5K | ★ 3.0M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $133,672,000.00 |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | N/A | $49.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.11 |
| 52 Week Low | $7.85 | $5.64 |
| 52 Week High | $9.55 | $13.53 |
Technical Indicators
Market Signals| Indicator | EMD | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 60.49 |
| Support Level | $10.71 | $8.13 |
| Resistance Level | $10.67 | $10.47 |
| Average True Range (ATR) | 0.12 | 0.62 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 95.45 | 66.93 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.